New Medical Technology at STHS Heart Targets Difficult-to-Control High Blood Pressure

Translate to Spanish or other 102 languages!

Dr. Luis Padula becomes the first cardiologist at South Texas Health System to perform a procedure using Symplicity Spyral™ technology, designed to reduce overactive nerves that contribute to hypertension. STHS Image
Dr. Luis Padula becomes the first cardiologist at South Texas Health System to perform a procedure using Symplicity Spyral™ technology, designed to reduce overactive nerves that contribute to hypertension. STHS Image
- Advertisement -

A new procedure offers long-term relief for patients struggling with severe high blood pressure that resists traditional drugs.

Affecting nearly 50% of U.S. adults, hypertension remains the leading contributor to death worldwide, according to the World Health Organization. 

Yet among Americans who know they have high blood pressure, roughly 80% do not have it adequately controlled, according to the Centers for Disease Control and Prevention, putting them at increased risk for life-threatening cardiovascular events.

- Advertisement -

“High blood pressure is often called the ‘silent killer’ because many people don’t experience symptoms until serious damage has already occurred,” said Luis Padula, MD, FACC, an interventional cardiologist with South Texas Health System (STHS) Clinics. “When left uncontrolled, hypertension can significantly increase the risk of heart attack, stroke, heart failure, kidney disease and other potentially life-threatening conditions. That’s why it’s so important for patients to work closely with their healthcare providers to manage their blood pressure and explore all available treatment options when lifestyle changes and medications alone are not enough.”

Unfortunately, apparent treatment-resistant hypertension (aTRH) affects nearly 20% of the treated hypertensive population in the U.S., according to the American Heart Association. 

Clinically defined as blood pressure that remains above 140/90 mmHg despite the concurrent use of three or more antihypertensive medications from different classes, including a diuretic, aTRH poses a significant threat to long-term health. 

Compared to patients whose blood pressure is more easily controlled, individuals with aTRH face a substantially higher risk of target-organ damage, serious cardiovascular complications and premature death.

- Advertisement -

“Because the vascular system remains under continuous, high-pressure stress, resistant hypertension takes a compounding toll on the body over time,” said Dr. Luis Padula. “Studies indicate that patients with treatment-resistant hypertension face approximately a 50% greater risk of experiencing major adverse cardiovascular and renal events.”

But there’s good news for Rio Grande Valley residents living with resistant hypertension. STHS Heart has introduced new, minimally invasive technology to help control high blood pressure. 

This summer, the facility treated its first patient with Symplicity Spyral™, a new renal denervation (RDN) system now offered for certain patients with high blood pressure. The elderly man has reported positive results following the procedure.

Approved by the U.S. Food and Drug Administration (FDA) in November 2023, the RDN system involves a minimally invasive procedure that targets nerves near the kidneys that can become overactive and cause high blood pressure. 

The procedure, which is also known as the Symplicity blood pressure procedure, is approved for use as an adjunctive treatment in patients with high blood pressure when lifestyle changes and antihypertensive medications do not adequately control blood pressure.

“It’s no secret that the Valley faces a high incidence of hypertension, with many people struggling to effectively control their condition,” said Dr. Padula. “Innovative therapies like Symplicity Spyral™ provide a promising new option for eligible patients whose blood pressure remains uncontrolled despite medication and lifestyle modifications, helping reduce long-term risks and improve overall cardiovascular health.”

“The Symplicity blood pressure procedure can provide patients with a blood pressure-reduction benefit that is ‘always on’ and does not require a permanent implant,” said Brenda Ivory, Chief Executive Officer, STHS Heart. “For patients who have worked tirelessly to manage their blood pressure without achieving adequate control, this technology offers new hope and peace of mind. We are proud to bring this innovative treatment to the Valley and look forward to helping more patients reduce their risk of serious cardiovascular complications.”

Since introducing the technology, STHS Heart, one of the first freestanding cardiology and cardiovascular hospitals built in the United States, has successfully completed an additional four procedures using the Symplicity Spyral system, expanding treatment options for patients with difficult-to-control hypertension.

If you or someone you know has high blood pressure that remains uncontrolled despite lifestyle changes and medication, talk to your healthcare provider to learn whether the Symplicity blood pressure procedure may be an appropriate treatment option. Individuals without a primary care physician can visitdoctors.southtexashealthsystem.com to find one near them.

To learn more about the comprehensive cardiovascular services available at STHS Heart, including the Symplicity blood pressure procedure, visit the facility’s website at www.southtexashealthsystemheart.com.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Robotic Surgery Program Expanded at STHS McAllen

From smaller incisions and less pain to shorter hospital stays and faster recovery times, robotic-assisted surgery is changing the way patients experience surgical care.

Texas Oncology to Host Breast Cancer Awareness Symposium in McAllen. FULL TO CAPACITY. NO MORE ROOM.

The Breast Cancer Awareness Symposium 2026 is an educational and networking event hosted by Texas Oncology and sponsored by Caris Life Sciences, bringing together oncology specialists, surgeons, advanced practice providers, and community healthcare professionals to discuss the latest advances in breast cancer prevention, diagnosis, treatment, survivorship, and reconstruction. The symposium's theme, "Breast Cancer 2026: Early Detection, Modern Care, and Survivorship Through Community Partnership," highlights the importance of multidisciplinary collaboration and patient-centered care

Highway Crash Leads to Unexpected STC Connection

What began as a flat tire on the side of a highway turned into a frightening collision and an unexpected encounter for South Texas College faculty member Jesus Amaya, when the paramedic who responded to the scene turned out to be one of STC’s graduates.

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.
- Advertisement -